成果報告書詳細
管理番号20110000001493
タイトル*平成22年度中間年報 基礎研究から臨床研究への橋渡し促進技術開発/橋渡し促進技術開発/遺伝子発現解析技術を活用した個別がん医療の実現と抗がん剤開発の加速
公開日2011/11/23
報告書年度2010 - 2010
委託先名一般社団法人バイオ産業情報化コンソーシアム 公立大学法人福島県立医科大学
プロジェクト番号P07022
部署名バイオテクノロジー・医療技術部
和文要約和文要約等以下本編抜粋:1.研究開発の内容及び成果等
(1)研究概要
独自開発の遺伝子発現解析技術による基礎研究成果を、がん臨床、さらには、抗がん剤開発現場へ橋渡しする。それにより、現在参画製薬企業が開発中の、および、臨床ですでに使用されている抗がん剤について、その効く・効かないを区別することのできる感受性遺伝子群を同定し、それらを治療方針決定用診断ツールとして活用した個別がん医療の実現を目指す。並びに、がん鑑別診断マーカーや創薬標的となる新たな遺伝子を同定し、それらに関する生物学的解析結果を含むデータをすみやかに参画製薬企業に開示することによって、各参画企業における新規がん治療薬開発の加速に資する。研究開発テーマは下記の通り。
(1) 細胞株を用いた抗がん剤感受性遺伝子群の同定
企業が開発中の抗がん剤、並びに、臨床で使用されている抗がん剤の感受性を評価できる遺伝子群を細胞株の遺伝子発現解析と薬剤感受性試験で同定する。
(2) 臨床がんサンプルを用いた抗がん剤感受性遺伝子群の有効性検証
臨床拠点および共同研究先で取得したがんサンプルの遺伝子発現解析を行い、臨床情報を統合したデータベースと照合解析し、上記感受性遺伝子群について、臨床での有効性を検証する。
(3)遺伝子発現情報の解析による創薬標的遺伝子等の同定
これら細胞株及び臨床がんサンプルの遺伝子発現情報を再解析し、同種がん内の多様性、個性に対応する新規がんマーカー遺伝子及び新規抗がん剤標的遺伝子を探索・同定する。
英文要約Title: Achievement of personalized medicine and acceleration of anti-cancer drug development by using the gene expression analysis technology (FY2007-FY2011) FY2010 Annual Report
 The result of a basic research of the original gene expression analysis technology is translated to the cancerous clinical medicine and anti-cancer drug development. About the anti-cancer drugs that are developing by the pharmaceutical company or using in the cancer medical treatment, the project will identify the sensitivity gene group that can distinguish between an effectiveness and non-effectiveness, and aim at the achievement of the personalized medicine as diagnosis tool for the treatment policy decision. And, the project will identify a new gene that becomes the cancer identification diagnosis marker and the drug development target, and also accelerate the development of the new cancer drug in the coordinated pharmaceutical company by disclosing these data to them promptly.
(1) Identification of anti-cancer drug sensitivity gene group by using the cell line
 For two anti-cancer drug candidates in development by participating companies gene expression profiles were obtained from the cell lines of the company, and the gene cluster analysis were attempted to extract the gene expression data sets which can distinguish between sensitivity and insensitivity. For one of two drug candidates completed the identification for the gene expression datasets and validation in clinical samples.
(2) Verification of effectiveness of anti-cancer drug sensitivity gene group by using the clinical cancer samples
 Fukushima Medical University and related hospitals gathered 2,628 clinical cancer samples from the project initiation to Feb. 2011 and 1,338 gene expression profiles were acquired among these samples. And, the profiles and clinical information on the samples were integrated to a data base system. Using the data base system the sensitivity gene groups that were identified in the above-mentioned research item were verified.
(3) Identification of a drug development target genes by analysis of gene expression information
Using the gene expression profiles the targeted genes showing elevated cancer-specific expression are narrowed. Among these genes two drug target genes based on search terms that meet the company's research and development strategy were found. This gene (all information including test results) were disclosed to the company.
 To analyze pathological tissue samples obtained previously stored and tissue samples for biopsy, various improvements was done to the gene expression analysis system. As a result for "a small amount of non-decomposed and non-degenerated" total RNA and "a very small amount decomposed and degenerated" total RNA the expression level in the sample could be analyzed by the new system.
 To enable the development of anticancer drugs using materials similar to clinical samples, new technologies that can subculture the clinical cancer tissues (prostate cancer) collected in the clinical site were established, and the construction of a new anti-cancer drug assessment system using the new cultured tissue were performed.
ダウンロード成果報告書データベース(ユーザ登録必須)から、ダウンロードしてください。

▲トップに戻る